Ilaris NIS in Korea
Recruiting
Observational Study
Hereditary Periodic Fever Syndromes
Cryopyrin-associated Periodic Syndromes (CAPS)
Colchicine Resistance Familial Mediterranean Fever (crFMF)
TNF Receptor Associated Periodic Syndrome (TRAPS)
Hyper-IgD Syndrome / Mevalonate Kinase Deficiency (HIDS/MKD)
Systemic Juvenile Idiopathic Arthritis (sJIA)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 2 – 100
- Sex
- Any
- Study type
- Observational
- Participants needed
- 25 (estimated)
- Sponsor
- Novartis Pharmaceuticals · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a study to evaluate safety and effectiveness of Ilaris in adult and pediatric patients receiving the drug in a clinical setting for any of the following indications, Hereditary Periodic Fever Syndromes, Cryopyrin-associated periodic syndromes (CAPS), colchicine resistance familial Mediterranean fever (crFMF), TNF receptor associated periodic syndrome (TRAPS), Hyper-IgD syndrome / Mevalonat…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Written informed consent/assent of the patient or their legal representative/parent (≥2 year and \<19 year-old pediatric patient) for voluntarily participating in this study
2. Age: ≥2 year and \<19 year-old pediatric and ≥19 year-old adult hereditary periodic fever syndrome …
Contacts
Novartis Pharmaceuticals
CONTACT